Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD)

Hematology

Volumn 12, Issue 2, 2007, Pages 141-147

  Giuseppe, Loverro ^a   Attilio, Guarini ^a   Edoardo, Di Naro ^a   Loredana, Giacomantonio ^a   Cristina, Lavopa ^a   Vincenzo, Liso ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

AMH; FSH; GnRH a; Inhibin B; LH; POF

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; FOLLITROPIN; GONADORELIN; INHIBIN B; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; PREDNISONE; PROCARBAZINE; TRIPTORELIN; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CELL COUNT; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FOLLITROPIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUATION; OVARY FUNCTION; OVARY INSUFFICIENCY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ADOLESCENT; ADULT; AMENORRHEA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; FEMALE; FOLLICLE STIMULATING HORMONE; GLYCOPROTEINS; HODGKIN DISEASE; HUMANS; INFERTILITY, FEMALE; INHIBINS; LUTEINIZING HORMONE; MECHLORETHAMINE; OVARIAN FAILURE, PREMATURE; OVARIAN FOLLICLE; OVARY; PREDICTIVE VALUE OF TESTS; PREDNISOLONE; PREDNISONE; PROCARBAZINE; SENSITIVITY AND SPECIFICITY; SURVIVORS; TESTICULAR HORMONES; TIME FACTORS; TRIPTORELIN; VINBLASTINE; VINCRISTINE;

EID: 34247183723     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330600954072     Document Type: Article

References (22)

1. Meirow, D. (2000) Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol, 169:1, pp. 123-131.
2. Chiarelli, AM, Marrett, LD and Darlington, G. (1999) Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario. Can Am J Epidemiol, 150, pp. 245-254.
3. Wallace, WH, Shalet, SM, Tetlow, LJ and Morris-Jones, PH (1993) Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. Med Pediatr Oncol, 21, pp. 333-339.
4. Glode, LM, Robinson, J. and Gould, SF (1981) Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin releasing hormone. Lancet, 1, pp. 1132-1134.
5. Champman, RM and Sutcliffe, S. (1986) The effects of chemotherapy and radiotherapy on fertility and their prevention. Recent Adv Clin Oncol, 2, pp. 239-251.
6. Krepart, GV and Lotocki, RJ (1986) Chemotherapy during pregnancy. Cancer in pregnancy, therapeutic guidelines, pp. 69-88. Futura Publishing, Mount Kisco, NY
7. Ataya, K., Rao, LV, Laurence, E. and Kimmel, R. (1995) Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in Rhesus monkeys. Biol Reprod, pp. 86-92.
8. Blumenfeld, Z., Avivi, I., Ritter, M. and Rowe, JM (1999) Preservation of fertility and ovarian function and minimizing chemiotherapy- induced gonadotoxicity in young women. J Soc Gynecol Invest, 6, pp. 229-239.
9. Blumenfeld, Z., Avivi, I., Linn, S., Epelbaum, R., Ben-Shahar, M. and Haim, N. (1996) Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemiotherapy. Hum Reprod, 11, pp. 1620-1626.
10. Blumenfeld, Z., Avivi, I., Ritter, M., Shariki, K. and Haim, N. (1998) Inhibin - A concentration in sera of young women durino following chemotherapy for lymphoma correlation with ovarian toxicity. Am J Reprod Immumol, 39, pp. 33-40.
11. Beerendonk, CC and Braat, DD (2005) Present and future options for the preservation of fertility in female adolescents with cancer. Endocr Dev, 8, pp. 166-175.
12. Waxman, JH, Ahmed, R., Smith, D., Wrigley, PF, Gregory, W. and Shalet, S. (1987) Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol, 19, pp. 159-162.
13. Blumenfeld, Z. and Haim, N. (1997) Prevention of gonadal damage during cytotoxic therapy. Ann Med, 29, pp. 199-206.
14. Blumenfeld, Z., Dann, E., Avivi, I., Epelbaum, R. and Rowe, M. (2002) Fertility after treatment for Hodgkin's disease. Ann Oncol, 13, pp. 138-147.
15. Pacheco, B Pereyra, Ribas, JM Mendez, Milone, G., Fernandez, I., Kvicala, R. and Mila, T. (2001) Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: A preliminary report. Gynecol Oncol, 81, pp. 391-397.
16. Yuce, MA, Kaplan, P Balkanli, Gucer, F., Doganay, L., Altaner, S. and Canda, T. (2004) Prevention of cyclophosphamide-induced ovarian damage by concomitant administration of GnRHa in mice: A dose-dependent relationship?. Eur J Gynaecol Oncol, 25:5, pp. 628-631.
17. Singh, K Lutchman, Davies, M. and Chatterjee, R. (2005) Fertility in female cancer survivors: Pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update, 11:1, pp. 69-89.
18. Couto-Silva, AC, Trivin, C., Thibaud, E., Esperou, H., Michon, J. and Brauner, R. (2001) Factors affecting gonadal function after bone marrow transplantation during childhood. Bone Marrow Transpl, 28:1, pp. 67-75.
19. Wolff, EF and Taylor, HS (2004) Value of the day 3 follicle-stimulating hormone measurement. Fertil Steril, 81:6, pp. 1486-1488.
20. Coussieu, C. (2004) Les inhibines dans l'hypofertilité féminine: Leur apport pour la pratique inhibins in woman's hypofertility: Practical interest. Gynécol Obstét Fertil, 32, pp. 760-766.
21. Tremellen, KP, Kolo, M., Gilmore, A. and Lekamge, DN (2005) Anti-mullerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol, 45:1, pp. 20-24.
22. Hendriks, DJ, Mol, BW, Bancsi, LF, Velde, ER Te and Broekmans, FJ (2005) Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: A meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril, 83:2, pp. 291-330.